Jul 2026
Abstract A017: FAP-Activated Prodrugs Target Cancer Stem Cells in Esophageal Adenocarcinoma
FAP-activated ponatinib prodrugs achieve selective, TME-compartmentalized delivery with substantially reduced systemic exposure and, when combined with the IAP antagonist 7532N as the TP101 regimen, provide a precision, stem cell-selective synthetic lethal strategy for this rare and aggressive malignancy.
Frank Mckeon, Wa Xian, Ruiwen Zhang et al.
· Cancer Research · 0 citations